Premium
Bioreductively Activated Lysyl Oxidase Inhibitors against Hypoxic Tumours
Author(s) -
Granchi Carlotta,
Funaioli Tiziana,
Erler Janine T.,
Giaccia Amato J.,
Macchia Marco,
Minutolo Filippo
Publication year - 2009
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.200900247
Subject(s) - lysyl oxidase , prodrug , hypoxia (environmental) , chemistry , in vitro , biochemistry , in vivo , cancer research , enzyme , pharmacology , biology , oxygen , organic chemistry , genetics
The right keys for tumour locks : Nitroaromatic and heteroaromatic portions are suitably sensitive to hypoxic conditions when used as BAPN masking groups, and the resulting prodrugs (pro‐BAPNs) showed good levels of in vitro hypoxia‐selective inhibition of lysyl oxidase (LOX) activity and cancer cell invasion.